[Federal Register Volume 83, Number 195 (Tuesday, October 9, 2018)]
[Notices]
[Pages 50666-50667]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-21764]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Peter Soukas, J.D., 301-594-8730; 
[email protected]. Licensing information and copies of the patent 
applications listed below may be

[[Page 50667]]

obtained by communicating with the indicated licensing contact at the 
Technology Transfer and Intellectual Property Office, National 
Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, 
Rockville, MD 20852; tel. 301-496-2644. A signed Confidential 
Disclosure Agreement will be required to receive copies of unpublished 
patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Hybridoma Cell Lines Producing Antibodies to RSV NS1

    Description of Technology: This technology provides a new set of 
hybridoma cell lines each expressing a single monoclonal antibody 
against human respiratory syncytial virus (RSV) nonstructural protein 1 
(NS1). These antibodies have variously been shown to detect NS1 protein 
in an enzyme-linked immunosorbent assay (ELISA), Western blot assay, 
immunofluorescence microscopy of paraformaldehyde-fixed cells, and flow 
cytometry. The various antibodies can vary in their efficiency in each 
of these assays. This technology provides a unique set of qualified 
monoclonal antibodies against RSV NS1 protein which currently do not 
exist. These antibodies and cell lines may be of interest to any 
persons investigating RSV infection processes, particularly as it 
relates to the activity of NS1 in such an infection process.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:
 Viral diagnostics
 Vaccine research
    Competitive Advantages:
 Ease of manufacture
 Unique research tool
    Development Stage:
 In vitro data assessment

    Inventors: Thomas McCarty (NIAID), Joseph Marcotrigiano (NIAID), 
Peter Collins (NIAID).
    Publications: None.
    Intellectual Property: HHS Reference No. E-018-2018/0--U.S. 
Provisional Application No. 62/661,320, filed April 23, 2018 (pending).
    Licensing Contact: Peter Soukas, J.D., 301-594-8730; 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize for development of a vaccine for 
respiratory or other infections. For collaboration opportunities, 
please contact Peter Soukas, J.D., 301-594-8730; [email protected].

    Dated: September 25, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2018-21764 Filed 10-5-18; 8:45 am]
 BILLING CODE 4140-01-P